Applied Therapeutics Inc (NAS:APLT)
$ 4.28 -0.12 (-2.73%) Market Cap: 489.06 Mil Enterprise Value: 356.63 Mil PE Ratio: 0 PB Ratio: 7.47 GF Score: 39/100

Applied Therapeutics Inc Corporate Update Call Transcript

Feb 16, 2023 / 01:30PM GMT
Release Date Price: $1.17 (+17.00%)
Operator

Welcome to Applied Therapeutics' SORD Deficiency Interim Data Conference Call. I would now like to turn the conference over to Dr. Shoshana Shendelman, Applied Therapeutics' Founder and CEO. Please go ahead.

Shoshana Shendelman
Applied Therapeutics, Inc. - CEO & Founder

Welcome, everyone, and thank you for joining us on today's call. With me on the call are Dr. Riccardo Perfetti, our Chief Medical Officer; Adam Hansard, our Chief Commercial Officer; and Dr. Michael Shy, Director of the Division of Neuromuscular Medicine at Carver College of Medicine, University of Iowa, and one of the original researchers responsible for identifying the genetic and pathophysiological cause of SORD deficiency. Dr. Shy is also the Principal Investigator on the INSPIRE Phase 3 trial.

Before we begin, let me remind you that today's conference call will be making forward-looking statements that represent the company's intentions, expectations, or beliefs concerning future events. These forward-looking statements are qualified by important factors set forth in today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot